Daphne Chylinski: Arousals During Sleep Are Strongly Linked to Alzheimer Disease Pathophysiology
Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.
Howard Fillit, MD: The Importance of Biomarkers for Alzheimer Disease
Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.
Krista Lanctot, PhD: Addressing Alzheimer Disease Agitation
The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.
Irina Pikuleva, PhD: Using Efavirenz in Alzheimer Disease
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.
Stephen Silberstein, MD: Understanding the Mechanism of Migraine
Silberstein spoke about the new mechanism-based treatments that are revolutionary in changing the treatment landscape of migraine.
FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS
Neurology News Network for the week of September 22, 2018.
Eugenia Trushina, PhD: Communication and Learning Through Collaboration
For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.
Paul Newhouse, MD: Exploring VU319 in Alzheimer Disease
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.
Howard Fillit, MD: Emphasizing Care in Alzheimer Disease
With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.
Ronald Crystal, MD: Introducing Genetics into Alzheimer Disease
Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?
Eugenia Trushina, PhD: Mitochondria as a Therapeutic Target for Alzheimer
The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.
Patricia Coyle, MD: Multiple Sclerosis Symptom Management
Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.
Howard Fillit, MD: Alzheimer Disease Drug Development Improvement
The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.
Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer Disease
The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.
Apathy and Risk of Dementia
A meta-analysis of 16 studies looked at the association between apathy in older individuals with and without incident dementia.
Patricia Coyle, MD: Needed Improvements in Multiple Sclerosis
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.
XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success
Neurology News Network for the week of September 15, 2018.
Patricia K. Coyle, MD: Early Multiple Sclerosis Identification
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.
Fred Lublin, MD: Beginning to Treat Progressive Multiple Sclerosis
The MS expert discussed the field's recent foray into treating progressive forms of the disease and what is in development.
Patricia K. Coyle, MD: Disease-Modification in Multiple Sclerosis
While there isn’t one agent Coyle believes is held above the rest, she noted that the oral therapies have become popular due to ease of administration.
Fred Lublin, MD: The Primary Care Partnership in Multiple Sclerosis
The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke about the relationship between primary care and specialists.
Peter Goadbsy, MD, PhD, DSc: Differentiating Between CGRPs, Synthesizing the Gepants
Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.
Fred Lublin, MD: The Need for Biomarkers in Multiple Sclerosis
The Saunders Family Professor of Neurology and the director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center discussed the need for biomarkers in MS.
Peter J. Goadsby, MD, PhD, DSc: Migraine Prevention Post-Approval of Erenumab
How did erenumab's approval by the FDA change the landscape of migraine treatment?
Kelvin Tsoi, PhD: Combination Therapy, Monotherapy in Alzheimer Disease
After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.
Lutz Frolich, MD, PhD: Learning from Negative Trials
Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.
James Hendrix, PhD: Progress and Challenges in the Alzheimer Space
Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.
Dennis Selkoe, MD: Current Challenges in Alzheimer Disease and Hope for the Future
Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.
Lutz Frolich, MD, PhD: Collaboration Between Clinicians and Industry
Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.
Nir Lipsman, MD, PhD: Innovations in Alzheimer Disease
The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.
